Prepared for distribution at the TRIAL BY JURY 2013 Program November 20, 2013 CONTENTS: VOLUME ONE PROGRAM SCHEDULE... 1-9 FACULTY BIOS... 1-13 1. ENSURING AN IMPARTIAL JURY IN THE AGE OF SOCIAL MEDIA... 1-57 Hon. Amy J. St. Eve United States District Court for the Northern District of Illinois Michael A. Zuckerman Jones Day 2. EFFECTIVE DEFENSE VOIR DIRE: MAKING SENSE OF JURORS EXPERIENCES... 1-89 Cynthia R. Cohen, Ph.D. Verdict Success 3. LET S TALK: ADDRESSING THE CHALLENGES OF INTERNET-ERA JURORS... 1-101 Julie Blackman, Ph.D. Ellen Brickman, Ph.D. DOAR Litigation Consulting 4. SCIENTIFIC JURY SELECTION: HISTORY, PRACTICE, AND CONTROVERSY... 1-113 Audrey Cleary Villanova University 5. JURY QUESTIONNAIRE, UNITED STATES DISTRICT COURT, SOUTHERN DISTRICT OF NEW YORK... 1-133 1-5
6. FRIEND OR FOE? SOCIAL MEDIA, THE JURY, AND YOU... 1-143 Leslie Ellis, Ph.D. TrialGraphix 7. JURY SELECTION MODEL VOIR DIRE QUESTIONS PROMULGATED BY DIRECTIVE #21-06 REVISED PROCEDURES AND QUESTIONS... 1-155 New Jersey Superior Court, Appellate Division 8. IN RE: VISA CHECK/MASTERMONEY ANTITRUST LITIGATION, JURY QUESTIONNAIRE... 1-185 9. HUNTSMAN CORPORATION v. CREDIT SUISSE SECURITIES (USA), L.L.C., ET AL., JURY QUESTIONNAIRE... 1-205 10. NOVARTIS PHARMACEUTICALS CORPORATION, INTERNATIONAL PHARMACEUTICAL LTD. v. TEVA PHARMACEUTICALS USA, INC., THE PARTIES PROPOSED VOIR DIRE... 1-221 11. PERSUASION IN OPENING STATEMENT, GENERATING INTEREST IN A CONVINCING MANNER... 1-235 James A. Johnson James A. Johnson, Esq. 12. SUCCEEDING IN THE OPENING STATEMENT... 1-243 Kenneth J. Melilli Creighton University School of Law 1-6
13. STORYTELLING IN LEGAL ARGUMENTS... 1-285 Robert D. Minick Keith C. Pounds TrialGraphix/Kroll Ontrack 14. LIBERTY MEDIA CORP. ET AL. v. VIVENDI UNIVERSAL S.A., ET AL., OPENING STATEMENT BY R. STAN MORTENSON... 1-295 R. Stan Mortenson Baker Botts LLP 15. LIBERTY MEDIA CORP. ET AL. v. VIVENDI UNIVERSAL S.A., ET AL., OPENING STATEMENT BY JIM QUINN... 1-365 Jim Quinn Weil, Gotshal & Manges LLP 16. NOVARTIS PHARMACEUTICALS CORPORATION, INTERNATIONAL PHARMACEUTICAL LTD. v. TEVA PHARMACEUTICALS USA, INC., OPENING STATEMENT BY EVAN R. CHESLER... 1-411 Evan R. Chesler 17. DIRECT EXAMINATION: MAKING THE FACTS UNDERSTANDABLE... 1-453 Frank C. Jones Chilton Davis Varner King & Spalding 18. AN IN-DEPTH LOOK AT DIRECT EXAMINATION OF EXPERT WITNESSES... 1-473 Deborah D. Kuchler Kuchler Polk Schell Weiner & Richeson, LLC 19. DIRECT EXAMINATION, A FORGOTTEN ART... 1-497 Jon R. Muth Miller Johnson 20. APPLE INC. v. SAMSUNG ELECTRONICS CO., LTD., ET AL., DIRECT EXAMINATION... 1-503 Joseph J. Mueller Wilmer, Cutler, Pickering, Hale and Dorr LLP 1-7
21. APPLE INC. v. SAMSUNG ELECTRONICS CO., LTD., ET AL., DIRECT EXAMINATION... 1-551 Harold J. McElhinny Morrison & Foerster LLP 22. NOVARTIS PHARMACEUTICALS CORPORATION, INTERNATIONAL PHARMACEUTICAL LTD. v. TEVA PHARMACEUTICALS USA, INC., DIRECT EXAMINATION... 1-589 23. ETHICAL PITFALLS IN JURY TRIALS... 1-665 Michael A. Jacobs Javier Serrano Morrison & Foerster LLP 24. ARMCHAIR JURY CONSULTANTS: THE LEGAL IMPLICATIONS AND BENEFITS OF ONLINE RESEARCH OF PROSPECTIVE JURORS IN THE FACEBOOK ERA... 1-683 Adam J. Hoskins University of Minnesota Law School 25. INTERNET INVESTIGATIONS OF JURORS: ETHICAL AND STRATEGIC CONSIDERATIONS... 1-709 Nancy E. Delaney Jeffrey C. Berman Louisa A. Fennell Curtis, Mallet-Prevost, Colt & Mosle 26. CROSS-EXAMINATION AT TRIAL: STRATEGIES FOR THE DEPOSITION... 1-717 Professor Gary S. Gildin The Dickinson School of Law of the Pennsylvania State University Program Attorney: Laurie Gilbertson 1-8
Prepared for distribution at the TRIAL BY JURY 2013 Program November 20, 2013 CONTENTS: VOLUME TWO PROGRAM SCHEDULE... 2-7 27. PENNSYLVANIA LEGAL AID NETWORK CROSS-EXAMINATION OF A LAY WITNESS... 2-11 Professor Gary S. Gildin The Dickinson School of Law of the Pennsylvania State University 28. TRIAL STRATEGY, PRIOR STATEMENTS... 2-43 Dan K. Webb J. David Reich Winston & Strawn 29. NOVARTIS PHARMACEUTICALS CORPORATION, INTERNATIONAL PHARMACEUTICAL LTD. v. TEVA PHARMACEUTICALS USA, INC., CROSS-EXAMINATION BY DAVID R. MARRIOTT... 2-49 30. IN RE: VIVENDI UNIVERSAL, S.A. SECURITIES LITIGATION, CROSS-EXAMINATION BY DANIEL SLIFKIN... 2-145 Daniel Slifkin 31. APPLE INC. v. SAMSUNG ELECTRONICS CO., LTD., ET AL., CROSS-EXAMINATION BY WILLIAM F. LEE... 2-401 William F. Lee Wilmer Cutler Pickering Hale and Dorr LLP 2-5
32. CLOSING ARGUMENT: THROUGH THE EYES OF A TRIAL ADVOCATE... 2-457 Kevin C. Kennedy The Kennedy Law Firm 33. CLOSING ARGUMENT FROM THE DEFENSE PERSPECTIVE... 2-477 Edgar M. Elliott, IV Christian & Small LLP 34. CRAFTING A SUCCESSFUL CLOSING ARGUMENT... 2-489 C. Barry Montgomery Bradley C. Nahrstadt Williams, Montgomery & John, Ltd. 35. IN RE: VIVENDI UNIVERSAL, S.A. SECURITIES LITIGATION, VIVENDI S CLOSING ARGUMENT WITH DEMONSTRATIVES... 2-499 Paul C. Saunders 36. NOVARTIS PHARMACEUTICALS CORPORATION, INTERNATIONAL PHARMACEUTICAL LTD. v. TEVA PHARMACEUTICALS USA, INC., PLAINTIFF S CLOSING ARGUMENT BY EVAN R. CHESLER... 2-709 Evan R. Chesler INDEX... 2-763 Program Attorney: Laurie Gilbertson 2-6